AXIM BIOTECH

Company Presentation

Winter 2022

OTCQB: AXIM

SAFE HARBOR

The statements made by Axim Biotechnologies Inc., in this presentation may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company's diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim's diagnostic products will receive clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use for use at the point-of-care and various other factors detailed from time to time in Axim's SEC reports and filings, including our Annual Report on Form 10-K filed on April 15 , 2021 and any subsequent quarterly reports on Form 10-Q and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

AXIM – POINT OF CARE DIAGNOSTICS

Diagnostics

- AXIM is an international diagnostic company pioneering the discovery and development of innovative point-of-care diagnostic solutions
- Partnering with Mayo Clinic and Arizona State

MAYO CLINIC

ASU Arizona State University

Eyes

- AXIM is working with two highly specialized point-of-care (POC) lab testing systems designed specifically to assist eye-care physicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders



COVID

- AXIM's COVID-19 neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells

Cancer

- AXIM is working on a blood test for the presence of a disease biomarker
- Unlike competitive technologies, the disease biomarker we test for is an enzyme not a circulating tumor cells (CTCs)

MARKET OPPORTUNITIES

$249B

Early Cancer Diagnostic Market

Global cancer diagnostics market size is expected to reach $249.6 billion by 2026, exhibiting a 7.0% during the forecast period

https://www.grandviewresearch.com/press-release/global-cancer-diagnostics-market

Dry Eye Disease Market

Global market is expected to grow at a CAGR of 6.6% during 2021-2026 and is expected to reach $6.1 Billion by 2024

https://www.imarcgroup.com/dry-eye-syndrome-market

$84B

COVID-19 Diagnostics Market

Global market is estimated at USD 84.4 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 3.1% from 2021 to 2027

https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market

DIAGNOSTIC ASSAY PIPELINE

PRODUCT	INDICATION	Pre-clinical	Phase 1	Phase 2	Phase 3	Submitted to FDA	FDA Cleared	Commercialization
Rapid Diagnostic Lateral Flow Test - Lactoferrin	Dry Eye Disease (DED)							Q1 2022
Rapid Diagnostic Lateral Flow Test - IGE	Dry Eye Disease (DED)							Q1 2022
ImmunoPass	COVID-19 Neutralizing Antibody Test							
TBD	Gen 2 COVID-19 Neutralizing Antibody Test							
Universal Cancer Biomarker	Detection cancer in blood (R&D Stage)							

AXIM EYE

- 20 million people in the United States (344 million people worldwide) have Dry Eye Disease
- Acquired two FDA Approved 510 (k)'s for Diagnostic Testing of Dry Eye Disease
- Tests are Non-invasive - Rapid Lateral Flow Assays using tears
- The first is a rapid (10-minute) lateral flow diagnostic assay that tests for exact levels of Lactoferrin through the collection of 0.5 microliter in tears
- The second is for the measurement of Ocular Immunoglobulin E (IgE), a biomarker for allergies and a key biomarker primarily associated with Dry Eye Disease
- Both tests are FDA-cleared and insurance reimbursable

EASY TO USE - POINT OF CARE - QUANTATITIVE TESTS

Using the Tear Capture Device, obtain 0.5µl of tears



Deposit tear sample in the cassette



Add 2 drops of chase buffer solution

Insert the cassette into the reader

10 minutes results will automaticaly appear

DRY EYE DISEASE MARKET

FDA Cleared Dry-Eye Tests	Company	Test Type	CLIA Level
Osmolarity	Tear Lab	Non-differential	Class I
Lactoferrin	AXIM	Differential	Class II
Tear IgE	AXIM	Differential	Class II
MMP9	Quidel	Yes/No	Class I
Adenovirus	Quidel	Yes/No	Class I

The global dry eye syndrome market size was $5.22 billion in 2019 and is projected to reach $6.54 billion by 2027, exhibiting a CAGR of 4.7% during the forecast period

https://www.fortunebusinessinsights.com/dry-eye-syndrome-market-102413

POINT-OF-CARE TESTING = FINANCIAL OPPORTUNITY

		LACTOFERRIN	IgE	Both
PER EYE	2021 CMS RATES	$17.27	$16.46	$33.73
	PRODUCT COST	$10.50	$10.50	$21.00
	GROSS PROFIT	$6.77	$5.96	$12.73
PER PATIENT	2021 CMS RATES	$34.54	$32.92	$67.46
	PRODUCT COST	$21.00	$21.00	$42.00
	GROSS PROFIT	$13.54	$11.92	$25.46

	#PATIENTS TESTED	NO RETEST	1 RETEST*
	PER DAY		
GROSS PROFIT POTENTIAL WITH 5 DAY WEEK AND 49 WEEK YEAR	1	**$6,110**	$9,224
	5	**$30,550**	$46,120
	10	**$61,100**	$76,667.00
	25	**$152,750**	$230,558.00
	50	**$305,500**	$461,176.00

* To test Treatment Efficacy assumes each patient comes back for one retest based on the results of the first tests. Only one test is performed - 65% were retested for Lactoferrin and 35% for IgE.

*Using current reimbursement rates, less the costs of the tests

Note: This is only an example of potential profitability from test strip reimbursements and is not an estimate for your practice. Related services such as exam revenues, drops, supplements and punctual plugs can more than double these estimates. **Contact your Rep or AXIM if you would like an estimate based on a more complete list of variables.** Any estimate provided by AXIM is for example purposes only and not a guarantee or predictor of actual results.

COVID-19 TESTING

DIVISION INFORMATION COVID PROGRAM

- AXIM's subsidiary Sapphire Biotech is a pioneer in the research and development of diagnostic tools for the early screening of cancer. Our researchers have been able to quickly adapt our existing research and products currently under development to create a diagnostic tool that screens for COVID-19 neutralizing antibodies

- The need for such an instrument is great as the pandemic continues to plague the worldwide healthcare landscape

NOT ALL ANTIBODIES ARE CREATED EQUAL

- Only neutralizing antibodies (**nAbs)** block binding and entry of the SARS-CoV-2 virus into human host cells
- However, despite recovering from the disease, not all individuals make high levels of Nabs
    - Up to 30% do not make measurable levels of NAbs
- The goal of all COVID-19 vaccines is to induce NAbs that block infection
- Our tests provide data on the efficacy of vaccine
- Our tests provide data on durability of the immunity



NAB LEVELS DECLINE AT DIFFERENT RATES AFTER VACCINATION



- Monitoring of Vaccine recipients (Pfizer and Moderna combined) after 2nd vaccine dose
- Each line is an individual vaccine recipient
- % Neutralization on the y-axis was calculated as 1-(Test line Density/LOD)*100%. LOD= 942,481

AXIM BIOTECH

LATERAL FLOW POC TEST



- Drop of whole blood
- Rapid: 10 minutes time to result
- Portable
- Inexpensive compared to laboratory tests
- Point-of-Care/At Home Testing/Telemedicine
- Monitors rise and fall in neutralizing antibodies in response to vaccine or natural infection
- Semi-Quantitative

94%
Sensitive

97%
Specific

LFA MANUFACTURING

Signed Distribution and Manufacturing Agreement

Empowered Diagnostics, Inc.

- Pompano Beach, Florida, USA
- Facility was the largest lateral flow pregnancy test manufacturer in the world
- Tech transfer complete
- EUA filed for Point-Of-Care with FDA
- Filed CE Mark for Europe
- Filed Health Canada
- Capable of manufacturing >7,000,000 tests a week

IMMUNOPASS


ImmunoPass
NEUTRALIZING ANTIBODY TEST
EASY TO USE
NAb RESULTS KEY
25 TESTS
ImmunoPass
NEUTRALIZING ANTIBODY TEST


ImmunoPass
COVID-19
NEUTRALIZING ANTIBODY TEST
RESULTS KEY
Low/No NAb
Moderate NAb
High NAb
Control
Result
Place Sample Here


immunopass
SARS-COV-2-NEUTRALIZING ANTIBODY RAPID TEST
Lot. No: 01-321-2020
Part No: NAB900-002
CONTENTS:
Test Cassettes with capillaries– 1
MANUFACTURED BY:
EMPOWERED DIAGNOSTICS
Empowered Diagnostics, LLC
3341 W. McNab Road, Pompano Beach, FL 33068
STORE AT ROOM TEMPERATURE | FOR RESEARCH USE ONLY
immunopass


EMPOWERED DIAGNOSTICS
CHASE BUFFER – 2 drs

ONCOLOGY

DIVISION INFORMATION ONCOLOGY

- Our diagnostic platform is driven by discovery of tumor-derived QSOX1-L biomarker in blood. QSOX1-L biomarker is not present, or present at low levels in healthy individuals. Quantitative tests that detect

- QSOX1-L will determine if levels correlate with i) stage of disease, ii) recurrence of disease and/or iii) response to therapy

ONCOLOGY MARKET SIZE

- The global oncology drugs market was valued at $128B in 2019, and is projected to reach $222B by 2027, registering a CAGR of **7.4%**

- QSOX1-L is over expressed in **10** cancers including lung, prostate, breast, brain, kidney, bladder, pancreatic
- Gives AXIM a pipeline for decades to come

https://www.alliedmarketresearch.com/oncology-cancer-drugs-market

QSOX1 HIGHLY SPECIFIC FOR MALIGNANT CANCERS



- We discovered (QSOX1) as a Biomarker in tumor derived proteins
- QSOX1 is over-expressed in multiple human cancers, it is not expressed or minimally expressed in non-malignant tissues

- Low cost, non-invasive Rapid Diagnostic Test for point-of-care for multiple cancers



- QSOX1 Levels in different sample pools

AXIM MANUFACTURES THE BIOLOGICS INTERNALLY

- BSL2 LAB IN SAN DIEGO
- AXIM foresaw the biologics supply chain problem early-on
- China - Expensive
- All Biological reagents are proprietary and manufactured in-house
- Our ACE2 is 10 times more potent and longer shelf life (patent pending)
- Creates additional line of revenue

MANAGEMENT TEAM

JOHN W. HUEMOELLER II CHAIRMAN, CHIEF EXECUTIVE OFFICER, PRESIDENT

Mr. Huemoeller has over 30 years' experience in financial markets and publicly traded companies including investment banking, corporate finance, executive management, sales and marketing, mergers and acquisitions, leveraged buyouts and private placements of securities.

JEFFERY BUSBY SENIOR VP BUSINESS DEVELOPMENT

Mr. Busby brings more than 30 years' experience developing and managing national and international ophthalmic medical device sales and support teams. Mr. Busby served for eight years as Chief Commercial Officer for Advanced Tear Diagnostics, Birmingham, AL., and most recently, Chief Revenue Officer Scanoptix, Charlottesville, VA.

ROBERT MALASEK CHIEF FINANCIAL OFFICER, SECRETARY

Mr. Malasek's experience includes serving as the Assistant Controller for Starwood Hotel & Resorts Worldwide, Inc., Controller for Pacific Crest Equity Partners (a private equity company), and Chief Financial Officer for NatureWell, Inc.

WORLD CLASS SCIENCE TEAM

JOSEPH TAUBER, MD

Recognized authority in the field of ocular surface diseases

SERGEI SVAROVSKY, PHD, MBA

Physical Chemist, with NCI, Pfizer Point-of-Care diagnostic projects Philips, Roche, Bio-Rad,

DOUGLAS LAKE, PHD

Associate Professor, ASU and Mayo Clinic. Molecular and Cellular Immunologist.

CATALINA VALENCIA, J.D.

Extensive management experience with biotech startups-leadership of early-stage Genentech.

MARIA GONZALEZ-MOA, PHD

Organic Chemist, Fellow NIH. Nanoparticle probes and lateral flow immunoassays. DDTD, Janssen and NanoComposix.

ALIM SEIT-NEBI, PHD

Molecular Biologist, Scripps Institute, develops our antibody and recombinant proteins and biomarkers

RENOWNED SCIENTIFIC MEDICAL ADVISORY BOARD

DR. KELLY K. NICHOLS, O.D., M.P.H., Ph. D.

A founding member of the Ocular Surface Society of Optometry, Dr. Nichols currently serves as Dean of the School of Optometry at The University of Alabama at Birmingham. She is an acknowledged expert on DED and Ocular Surface Disease and has been extensively published. She earned her second B.S. and a Doctor of Optometry (O.D.) at UC Berkeley, and an M.P.H in biostatistics and a Ph.D. in Vision Science at Ohio State University.

DR. LAURA M. PERIMAN, MD

Dr. Periman brings 30 years' experience in medicine, the last 20 of which include her clinical practice specializing in ocular surface disease and dry eye disease (DED). She serves as Founder and Director of Dry Eye Services and Clinical Research of the Seattle-based Periman Eye Institute. Additionally, she has served as a principal investigator in ophthalmic clinical research primarily centered on ocular surface disease innovations including neural stimulation for treating DED, novel topical therapeutics as well as innovative procedures such as IPL, Radiofrequency and more.

CHAIRMAN

JOSEPH TAUBER, MD

Recognized authority in the field of ocular surface diseases

DR. HENRY D. PERRY, MD

A recipient of the Life Achievement Award from the American Academy of Ophthalmology, Dr. Perry is recognized as one of the US' leading cornea and refractive surgeons. He serves as Senior Founding Partner, Ophthalmic Consultants of Long Island as well as Chief, Cornea Service, Nassau University Medical Center, New York. He has won numerous Best Doctor awards and was recently recognized as one of the top 150 Ophthalmologists in America by "Newsweek" magazine in 2021.

DR. MICHAEL E. STERN, MS, Ph. D.

Dr. Stern brings over 30 years of senior scientific, research, academic and executive level expertise with Dry Eye Disease and Ocular Surface Disease (OSD). Currently, he is a Principal and Chief Science Officer for immunEyze, a boutique contract research organization that performs preclinical and clinical research for OSD indications. Previously, he served for 26 years with Allergan where he rose to Principal Scientist and Vice-President Inflammation Research whose work included elucidating the pathophysiology of DED. He is extensively published in leading ocular journals.

NEAR & MID TERM OBJECTIVES

- Creating new marketing materials, planning launch 1st Q 2022
- Revenue generation through FDA approved DED diagnostics
- CLIA Waiver Application
- Awaiting FDA approval on EUA
- Clinical studies for Gen 2 Antibody Test
- Achieving profitability in end of 2022

COMPELLING OPPORTUNITY

- AXIM has a world-class science team
- We anticipate strong demand for our Covid test that measures neutralizing antibodies
- Our Covid test is fast, portable and inexpensive
- Able to manufacture 7 million tests a week
- Five COVID-19 related patents pending - 4 for cancer, 1 issued
- Product pipeline – Dry Eye, Cancer, Covid-19

AXIM BIOTECH

FOR FURTHER INFORMATION, PLEASE CONTACT:

John Huemoeller II – CEO
Tel. +1 858-923-4422
info@aximbiotech.com
www.aximbiotech.com